Gift of the GABA? Transmitter Nixes Neurogenesis in APP, ApoE4 Mice
treatment.”—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2303 Alzheimer's Disease Stem
ALL NEWS
373 RESULTS
You searched Landhuis
Sort By:
- Most Recent
- Most Commented
- Most Relevant
ADNI: Mission Creep From Alzheimer Disease to Healthy Senior?
Scientists don’t own their data.”—Esther Landhuis. This concludes our two-part series. See also Part 1. None
As AD Trials Come of Age, Will Cognitive Tests Follow Suit?
things, quite frankly. We've been looking at the ADAS-Cog for 15 years.”—Esther Landhuis. None
Las Vegas: Can Collaboration Speed Drug Discovery for FTD?
with the Clinical Trials on Alzheimer’s Disease Conference, 3-5 November 2011 in San Diego.—Esther Landhuis
In Big Picture, Familial AD’s Biomarker Data Resemble LOAD
and assessing effects of therapy would be easier and quicker?” he wrote to Alzforum.—Esther Landhuis. None
San Diego: Tau Oligomer Antibodies Relieve Motor Deficits in Mice
on humans than simply the Aβ vaccine.”—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2617
San Francisco: Gladstone Institute Hosts Tau Powwow
Landhuis. This is Part 1 of a four-part series. See also Part 2, Part 3, Part 4. Read the PDF of the entire
Innate Immune Cells Enlisted to Clear Amyloid, Fight Disease
cord express TMEM119 RNA, and the protein is highly restricted to microglia.—Esther Landhuis None
AD Immunotherapy: Toward Prevention, DNA-based Vaccines?
and join the discussion.—Esther Landhuis. Esther Landhuis is a science writer in Dublin, California.
PPMI: Parkinson's Field’s Answer to ADNI
of therapeutics more rapidly and effectively in future trials.”—Esther Landhuis. This is Part 1 of a two-part
Las Vegas: Are Frontotemporal Dementia Models Fit for Pharma?
in terms of recapitulating FTD phenotype,” Boxer told ARF.—Esther Landhuis. This is Part 2 of a three-part
San Francisco: Tau—Time to Shine as Therapeutic Target?
Landhuis. This concludes a four-part series. See also Part 1, Part 2, and Part 3. Read the PDF of the entire
Wave of New BACE Inhibitors Heading to Phase 2
forward with these compounds in clinical trials.”—Esther Landhuis. None